Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552887 | 0.92 | MTNR1A (0.42) | MTNR1AMTNR1BHTR2ATRPV1HTR2C | |
| SCHEMBL8016986 | 0.91 | HTR1A (0.42) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL6099019 | 0.90 | ALDH1A1 (0.44) | MTNR1AMTNR1BHTR2A | |
| SCHEMBL1180547 | 0.89 | MTNR1A (0.44) | MTNR1AMTNR1BCYP1A2CYP2A6 | |
| SCHEMBL1304599 | 0.86 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL19616461 | 0.83 | CYP1A2 (0.45) | CYP1A2CYP2A6 | |
| SCHEMBL8499741 | 0.83 | KDM4E (0.49) | — | |
| SCHEMBL31505094 | 0.83 | CYP1A2 (0.45) | CYP1A2CYP2A6 | |
| SCHEMBL30344940 | 0.82 | DRD2 (0.36) | CYP1A2CYP2A6 | |
| SCHEMBL5369468 | 0.82 | DRD2 (0.36) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010015745-A1 | NOVEL METHOD FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036162-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MTNR1A 3560/4885MTNR1B 2255/4885HTR2A 4846/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | MTNR1A 3560/4885MTNR1B 2255/4885HTR2A 4846/4885 |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | MTNR1A 25/4885MTNR1B 30/4885HTR2A 22/4885 |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | PPARG, PPARA, FABP4 | MTNR1A 1151/4885MTNR1B 749/4885HTR2A 980/4885 |
| US-20100036162-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | MTNR1A 331/4885MTNR1B 293/4885HTR2A 49/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MTNR1A 3560/4885MTNR1B 2255/4885HTR2A 4846/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MTNR1A 1634/4885MTNR1B 1562/4885HTR2A 3119/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MTNR1A 3560/4885MTNR1B 2255/4885HTR2A 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.